National high prevalence, and low awareness, treatment and control of dyslipidaemia among people aged 15–69 years in Mongolia in 2019

Abstract

The aim of the study was to evaluate the prevalence, distribution and correlates of dyslipidaemia among people (15–69 years) in Mongolia. National data were analyzed from 4,895 individuals (15–69 years, median age = 35 years) that took part in the Mongolia cross-sectional STEPS survey in 2019, and had complete lipid measurements. Dyslipidaemia was defined using the guidelines of the Adult Treatment Panel III. The prevalence of dyslipidaemia was 58.6%, 31.7% high triglycerides (TG), 26.9% high low-density lipoprotein cholesterol (LDL-C), 26.9% high total cholesterol (TC) and 14.6% low high-density lipoprotein cholesterol (HDL-C). Among those with dyslipidaemia, 6.2% were aware. Among those who were aware, the proportion of lipid-lowering drug treatment was 18.9% and among those who took lipid-lowering drugs, 21.5% had their dyslipidaemia controlled. In adjusted logistic regression, older age (40–69 years) (AOR: 1.19, 95% CI 1.02–1.40), urban residence (AOR: 1.24, 95% CI 1.04–1.48), obesity call II (AOR: 2.89, 95% CI 2.29–3.66), hypertension (AOR: 1.33, 95% CI 1.11–1.59), and diabetes (AOR: 1.62, 95% CI 1.20–2.18) were positively, and male sex (AOR: 0.84, 95% CI 0.72–1.00) was negatively associated with dyslipidaemia prevalence. Six in ten Mongolians 15 years and older had dyslipidaemia. Several factors associated with dyslipidaemia that can be used to target public health interventions were identified.